Plain-English translation of NCT07179328 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new procedure using focused ultrasound (sound waves aimed precisely at your tumor) combined with a contrast agent called DEFINITY to temporarily open the blood-brain barrier — a natural shield that normally prevents chemotherapy drugs from reaching brain tumors. The goal is to help your standard chemotherapy drug (temozolomide) work more effectively by allowing more of it to reach the tumor.
Glioblastoma is a serious brain tumor, and chemotherapy drugs often can't penetrate the blood-brain barrier to reach the tumor effectively. This trial is exploring whether this new ultrasound technique can safely create temporary openings in that barrier so the medication can work better.
You likely qualify if…
You likely don't qualify if…
You would receive up to 6 ultrasound treatment sessions spaced 4 to 6 weeks apart over about 6 to 8 months, with each session timed during your regular chemotherapy appointments. At each session, you would receive an injection of the contrast agent, then undergo the focused ultrasound procedure guided by MRI imaging to ensure precision. Throughout the study, you would have regular medical check-ups, blood tests, and imaging scans to monitor your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Canada